Fibromuscular dysplasia classification

Fibromuscular dysplasia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Fibromuscular dysplasia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiorgram
X-ray
CT
MRI
Arteriography
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Management Guidelines
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
ASA/ACCF/AHA Guideline Recommendations
Management of Patients With Fibromuscular Dysplasia of the Extracranial Carotid Arteries
Case Studies
Case #1
Fibromuscular dysplasia classification On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Fibromuscular dysplasia classification All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Fibromuscular dysplasia classification
CDC on Fibromuscular dysplasia classification
Fibromuscular dysplasia classification in the news
Blogs on Fibromuscular dysplasia classification
Directions to Hospitals Treating Fibromuscular dysplasia
Risk calculators and risk factors for Fibromuscular dysplasia classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohsen Basiri M.D.

Overview

The classification system for fibromuscular dysplasia (FMD) was first according to the arterial layer involved. (intima, media, or adventitia) [18-20]. However, with use of TPA for treatment and its preference rather than surgery, the obtaining of pathological specimens are restricted.Thus,today, FMD is a disease diagnosed radiographically and histopathological classification has been replaced by an arteriographicfindings [3]. 3. Olin JW, Gornik HL, Bacharach JM, et al. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scienti􀉹c statement from the American Heart Association. Circulation 2014; 129:1048. 20. Lüscher TF, Lie JT, Stanson AW, et al. Arterial 􀉹bromuscular dysplasia. Mayo Clin Proc 1987; 62:931

Classification

fghjkjjhfrsdxck8i7tg uythci75hygf loi[ ;

• There is no established system for the classification of [disease name].

OR

• [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
  • [Group1]
  • [Group2]
  • [Group3]
  • [Group4]

OR

• [Disease name] may be classified into [large number > 6] subtypes based on:
  • [Classification method 1]
  • [Classification method 2]
  • [Classification method 3]
• [Disease name] may be classified into several subtypes based on:
  • [Classification method 1]
  • [Classification method 2]
  • [Classification method 3]

OR

• Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

OR

• If the staging system involves specific and characteristic findings and features:
• According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

OR

• The staging of [malignancy name] is based on the [staging system].

OR

• There is no established system for the staging of [malignancy name].